Rodatristat Ethyl Decreases Activity in Pulmonary Arterial Hypertension: Results from the ELEVATE-2 Trial

Abstract Rationale Wearable devices provide an objective measurement of activity in the home setting and are complementary to 6-minute walk distance. Pulmonary arterial hypertension (PAH) patients have low daily activity time which is likely related to physiologic impairment and behavioral changes. Actigraphy may be a functional outcome assessment capable of detecting changes in activity mediated by improvement in physiology in a therapy trial. Objective ELEVATE-2 was a Phase 2 trial evaluating rodatristat ethyl versus placebo in PAH. We hypothesized rodatristat ethyl would improve measures of activity, specifically Peak Steps, at Week 24, and further that changes in actigraphy measures would correlate with changes in stroke volume index. Methods ELEVATE-2 was a randomized, double blinded, placebo-controlled trial. All participants wore ActiGraph on their wrist. We compared changes in average Peak 5-minute Steps (steps during the most active 5 minutes of a day, whether or not consecutive), daily steps, moderate activity time, and vigorous activity time at baseline, week 12, and week 24. Linear mixed methods with repeated measures were performed to assess treatment-time interaction at week 24, and least squares means were used to compare groups. Linear regression was performed to evaluate the changes in stroke volume index on activity parameters. Results Of the 108 participants, 100 were included in the analysis. Adjusted least-squares mean showed Peak 5-minute steps (-49 steps (-80 to -18)), moderate activity time (-17.3 minutes/day (-29.3 to -5.3)), and daily steps (-656 (-1,171 to -140)) all decreased at week 24 after treatment with rodatristat ethyl compared to placebo. Peak 5-minute steps were weakly associated with changes in stroke volume index, 0.74 (0.11 to 1.37). Conclusion Rodatristat ethyl reduced multiple activity parameters in this small but randomized, multi-center study. Peak steps, daily steps, and moderate activity time seem to capture different aspects of movement in the home setting. Activity parameters were not strongly associated with resting hemodynamics, underscoring the influence of behavioral and external factors on activity.

Authors

Institutions

Publication Details

Journal
Annals of the American Thoracic Society
Published
2026-01-23
DOI
https://doi.org/10.1093/annalsats/aaoaf066
Citations
1
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
36.44
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Rodatristat Ethyl Decreases Activity in Pulmonary Arterial Hypertension: Results from the ELEVATE-2 Trial

Ed Parsley, Robert E. Block, Howard M. Lazarus, S. Sahay et al.
1 citations
Annals of the American Thoracic Society
Pulmonary Hypertension Research and Treatments
36.44
article

Rodatristat Ethyl Decreases Activity in Pulmonary Arterial Hypertension: Results from the ELEVATE-2 Trial

Ed Parsley, Robert E. Block, Howard M. Lazarus, S. Sahay, Deborah J. Ossip, Jill Denning, Daniel J Lachant, R James White
article en
1 citations

Abstract

Abstract Rationale Wearable devices provide an objective measurement of activity in the home setting and are complementary to 6-minute walk distance. Pulmonary arterial hypertension (PAH) patients have low daily activity time which is likely related to physiologic impairment and behavioral changes. Actigraphy may be a functional outcome assessment capable of detecting changes in activity mediated by improvement in physiology in a therapy trial. Objective ELEVATE-2 was a Phase 2 trial evaluating rodatristat ethyl versus placebo in PAH. We hypothesized rodatristat ethyl would improve measures of activity, specifically Peak Steps, at Week 24, and further that changes in actigraphy measures would correlate with changes in stroke volume index. Methods ELEVATE-2 was a randomized, double blinded, placebo-controlled trial. All participants wore ActiGraph on their wrist. We compared changes in average Peak 5-minute Steps (steps during the most active 5 minutes of a day, whether or not consecutive), daily steps, moderate activity time, and vigorous activity time at baseline, week 12, and week 24. Linear mixed methods with repeated measures were performed to assess treatment-time interaction at week 24, and least squares means were used to compare groups. Linear regression was performed to evaluate the changes in stroke volume index on activity parameters. Results Of the 108 participants, 100 were included in the analysis. Adjusted least-squares mean showed Peak 5-minute steps (-49 steps (-80 to -18)), moderate activity time (-17.3 minutes/day (-29.3 to -5.3)), and daily steps (-656 (-1,171 to -140)) all decreased at week 24 after treatment with rodatristat ethyl compared to placebo. Peak 5-minute steps were weakly associated with changes in stroke volume index, 0.74 (0.11 to 1.37). Conclusion Rodatristat ethyl reduced multiple activity parameters in this small but randomized, multi-center study. Peak steps, daily steps, and moderate activity time seem to capture different aspects of movement in the home setting. Activity parameters were not strongly associated with resting hemodynamics, underscoring the influence of behavioral and external factors on activity.

Annals of the American Thoracic Society
University of Rochester Medical Center (US), Athira Pharma (United States) (US), Methodist Hospital (US), Tris Pharma (United States) (US)
Good health and well-being
Openalex Percentile: Top 1%
Pulmonary Hypertension Research and Treatments
36.44
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.